dc.creator | Fernández-Cuenca, Felipe | es |
dc.creator | López Hernández, Inmaculada | es |
dc.creator | Cercenado, Emilia | es |
dc.creator | Conejo Gonzalo, Mª Carmen | es |
dc.creator | Tormo, Nuria | es |
dc.creator | Gimeno, Concha | es |
dc.creator | Pascual Hernández, Álvaro | es |
dc.date.accessioned | 2023-01-10T15:18:33Z | |
dc.date.available | 2023-01-10T15:18:33Z | |
dc.date.issued | 2021-02-08 | |
dc.identifier.citation | Fernández-Cuenca, F., López Hernández, I., Cercenado, E., Conejo Gonzalo, M.C., Tormo, N., Gimeno, C. y Pascual Hernández, Á. (2021). Reporting antimicrobial susceptibilities and resistance phenotypes in Staphylococcus spp.: a nationwide proficiency study. Journal of Antimicrobial Chemotherapy, 76 (5), 1187-1196. https://doi.org/10.1093/jac/dkab017. | |
dc.identifier.issn | 0305-7453;1460-2091 | es |
dc.identifier.uri | https://hdl.handle.net/11441/141095 | |
dc.description.abstract | Objectives
To evaluate the proficiency of microbiology laboratories in Spain in antimicrobial susceptibility testing (AST) of Staphylococcus spp.
Materials and methods
Eight Staphylococcus spp. with different resistance mechanisms were selected: six Staphylococcus aureus (CC-01/mecA, CC-02/mecC, CC-03/BORSA, CC-04/MLSBi, CC-06/blaZ and CC-07/linezolid resistant, cfr); one Staphylococcus epidermidis (CC-05/linezolid resistant, 23S rRNA mutation); and one Staphylococcus capitis (CC-08/daptomycin non-susceptible). Fifty-one laboratories were asked to report: (i) AST system used; (ii) antimicrobial MICs; (iii) breakpoints used (CLSI or EUCAST); and (iv) clinical category. Minor, major and very major errors (mEs, MEs and VMEs, respectively) were determined.
Results
The greatest MIC discrepancies found were: (i) by AST method: 19.4% (gradient diffusion); (ii) by antimicrobial agent: daptomycin (21.3%) and oxacillin (20.6%); and (iii) by isolate: CC-07/cfr (48.0%). The greatest error rates were: (i) by AST method: gradient diffusion (4.3% and 5.1% VMEs, using EUCAST and CLSI, respectively); (ii) by breakpoint: 3.8% EUCAST and 2.3% CLSI; (iii) by error type: mEs (0.8% EUCAST and 1.0% CLSI), MEs (1.8% EUCAST and 0.7% CLSI) and VMEs (1.2% EUCAST and 0.6% CLSI); (iii) by antimicrobial agent: VMEs (4.7% linezolid and 4.3% oxacillin using EUCAST); MEs (14.3% fosfomycin, 9.1% tobramycin and 5.7% gentamicin using EUCAST); and mEs (22.6% amikacin using EUCAST).
Conclusions
Clinical microbiology laboratories should improve their ability to determine the susceptibility of Staphylococcus spp. to some antimicrobial agents to avoid reporting false-susceptible or false-resistant results. The greatest discrepancies and errors were associated with gradient diffusion, EUCAST breakpoints and some antimicrobials (mEs for aminoglycosides; MEs for fosfomycin, aminoglycosides and oxacillin; and VMEs for linezolid and oxacillin). | es |
dc.format | application/pdf | es |
dc.format.extent | 10 p. | es |
dc.language.iso | eng | es |
dc.publisher | Oxford University Press | es |
dc.relation.ispartof | Journal of Antimicrobial Chemotherapy, 76 (5), 1187-1196. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | phenotype | es |
dc.subject | gentamicin sulfate (usp) | es |
dc.subject | amikacin | es |
dc.subject | diffusion | es |
dc.subject | chromatography | es |
dc.subject | micellar electrokinetic capillary | es |
dc.subject | daptomycin | es |
dc.subject | fosfomycin | es |
dc.subject | gentamicins | es |
dc.subject | laboratory | es |
dc.subject | oxacillin | es |
dc.subject | staphylococcus | es |
dc.subject | microbiology | es |
dc.subject | tobramycin | es |
dc.subject | linezolid | es |
dc.subject | antimicrobials | es |
dc.subject | chief complaint | es |
dc.subject | malnutrition-inflammation-cachexia syndrome | es |
dc.title | Reporting antimicrobial susceptibilities and resistance phenotypes in Staphylococcus spp.: a nationwide proficiency study | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Microbiología | es |
dc.relation.projectID | RD 16/0016 | es |
dc.relation.publisherversion | https://academic.oup.com/jac/article/76/5/1187/6130710 | es |
dc.identifier.doi | 10.1093/jac/dkab017 | es |
dc.journaltitle | Journal of Antimicrobial Chemotherapy | es |
dc.publication.volumen | 76 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 1187 | es |
dc.publication.endPage | 1196 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |